Earnings summaries and quarterly performance for EAGLE PHARMACEUTICALS.
Research analysts covering EAGLE PHARMACEUTICALS.
Recent press releases and 8-K filings for EGRX.
Eagle Pharmaceuticals Divests Barhemsys Marketing Authorization
EGRX
M&A
- Eagle Pharmaceuticals (EGRX) has divested the U.S. marketing authorization for Barhemsys to LXO Group.
- Barhemsys is the sole FDA-approved treatment for Postoperative Nausea and Vomiting (PONV), launched in November 2020.
- Eagle Pharmaceuticals stated this divestiture reflects its commitment to streamlining its acute care business and maximizing shareholder value, with the cash proceeds used for ongoing business operations.
Jan 14, 2026, 3:21 PM
Quarterly earnings call transcripts for EAGLE PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more